Related Experiment Video
Updated: Jul 20, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Update on the management of cardiogenic shock
1University Of Minnesota, College of Pharmacy, Department of Experimental and Clinical Pharmacology, Minneapolis, Minnesota, USA. HMann@umn.edu
Insights
Cardiogenic shock, a severe complication of acute myocardial infarction, has a high mortality rate. Early reperfusion and supportive treatments are critical, with emerging pharmacologic therapies showing promise for improved outcomes.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Cardiogenic shock is a frequent and life-threatening emergency associated with acute coronary syndromes.
- Delayed myocardial reperfusion after acute myocardial infarction significantly increases the risk and mortality of cardiogenic shock.
Purpose of the Study:
- To review recent advancements in the pathophysiology, incidence, and treatment of cardiogenic shock.
- To highlight recent pharmacologic advances in managing cardiogenic shock.
Main Methods:
- Literature review summarizing recent findings on cardiogenic shock.
- Focus on pharmacologic interventions and supportive treatments.
Main Results:
- Cardiogenic shock affects 5-10% of myocardial infarction patients, with mortality exceeding 50%.
- Early reperfusion and supportive care (vasopressors, inotropes, fluids) are crucial, despite treatment standard variations.
- Overall mortality has decreased, but incidence remains constant.
Conclusions:
- Early revascularization combined with emerging pharmacological therapies may improve outcomes.
- Timely transport and treatment, prioritizing revascularization, are essential for cardiogenic shock patients.
Purpose Of Review:
Cardiogenic shock is a life-threatening emergency that occurs frequently with acute coronary syndromes. If rapid myocardial reperfusion following acute myocardial infarction is not obtained, either with thrombolytics or by revascularization, cardiogenic shock frequently develops and the mortality rate is high. This review summarizes recent advances in the pathophysiology, incidence and treatment of cardiogenic shock. Particular attention is given to pharmacologic advances.
Recent Findings:
Cardiogenic shock continues to occur in 5-10% of patients who suffer a myocardial infarction and the mortality remains over 50% in most studies. Treatment preference is referral to a cardiac center capable of reperfusion using multiple therapies. While no delay in reperfusion is acceptable, emphasis on implementing supportive treatment such as vasopressors, inotropes, and fluids remains critical. There is a wide variance in treatment standards despite established guidelines. Overall mortality from cardiogenic shock has decreased but the incidence remains unchanged.
Summary:
Emerging pharmacological interventions designed to counteract the underlying proinflammatory pathophysiologic mechanisms may, in combination with early revascularization, result in improved patient outcomes, but there is no magic bullet on the horizon. Attention to the timeliness of transport and treatment of patients with a focus on revascularization is required for cardiogenic shock patients.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure V: Medical Management
Acute Coronary Syndrome IV: Interprofessional Care
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management
Cardiomyopathy VII: Pre and Post Operative Nursing Management
